Touyun Biotech Group Limited
HKEX:1332.HK
0.154 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 198.64 | 315.825 | 283.505 | 206.786 | 342.696 | 348.77 | 317.699 | -37.623 | 285.967 | 397.04 | 436.402 | 389.304 | 418.66 |
| Cost of Revenue
| 142.036 | 195.706 | 176.451 | 122.172 | 217.202 | 254.09 | 279.925 | 236.457 | 280.722 | 330.786 | 366.93 | 318.099 | 332.735 |
| Gross Profit
| 56.604 | 120.119 | 107.054 | 84.614 | 125.494 | 94.68 | 37.774 | -274.08 | 5.245 | 66.254 | 69.472 | 71.205 | 85.925 |
| Gross Profit Ratio
| 0.285 | 0.38 | 0.378 | 0.409 | 0.366 | 0.271 | 0.119 | 7.285 | 0.018 | 0.167 | 0.159 | 0.183 | 0.205 |
| Reseach & Development Expenses
| 22.293 | 20.28 | 21.931 | 20.868 | 17.308 | 33.339 | 29.188 | 3.148 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 118.007 | 128.249 | 126.081 | 121.544 | 135.51 | 207.708 | 138.368 | 74.789 | 42.078 | 39.289 | 37.08 | 32.841 | 27.913 |
| Selling & Marketing Expenses
| 23.707 | 26.431 | 18.66 | 17.66 | 23.012 | 31.645 | 34.17 | 17.568 | 13.468 | 15.142 | 16.049 | 14.688 | 14.969 |
| SG&A
| 141.714 | 154.68 | 144.741 | 139.204 | 158.522 | 239.353 | 172.538 | 92.357 | 55.546 | 54.431 | 53.129 | 47.529 | 42.882 |
| Other Expenses
| 0 | -2.735 | 3.455 | -2.97 | 4.119 | -0.127 | -0.1 | 0.093 | -82.41 | 1.099 | 0.456 | 0.933 | 0.888 |
| Operating Expenses
| 146.923 | 151.945 | 144.741 | 136.234 | 158.522 | 239.226 | 172.438 | 92.037 | 55.205 | 54.134 | 52.396 | 46.997 | 41.972 |
| Operating Income
| -90.319 | -26.546 | -35.305 | -73.171 | -122.814 | -147.137 | -186.665 | -645.151 | -132.264 | 11.819 | 15.021 | 23.753 | 43.189 |
| Operating Income Ratio
| -0.455 | -0.084 | -0.125 | -0.354 | -0.358 | -0.422 | -0.588 | 17.148 | -0.463 | 0.03 | 0.034 | 0.061 | 0.103 |
| Total Other Income Expenses Net
| -182.266 | -159.453 | -85.283 | -120.363 | -161.868 | -104.837 | -114.323 | -741.721 | 357.923 | 1.036 | 3.369 | 2.802 | 3.712 |
| Income Before Tax
| -272.585 | -199.183 | -122.97 | -171.983 | -194.896 | -251.974 | -248.987 | -1,107.838 | 256.263 | 13.156 | 19.712 | 26.171 | 46.421 |
| Income Before Tax Ratio
| -1.372 | -0.631 | -0.434 | -0.832 | -0.569 | -0.722 | -0.784 | 29.446 | 0.896 | 0.033 | 0.045 | 0.067 | 0.111 |
| Income Tax Expense
| -0.016 | 3.473 | 0.971 | 0.006 | 4.213 | 1.989 | 4.229 | 0.026 | 1.06 | 1.766 | 2.78 | 3.256 | 4.931 |
| Net Income
| -268.939 | -202.656 | -123.941 | -171.989 | -199.109 | -253.963 | -253.216 | -1,150.825 | 255.259 | 10.349 | 13.435 | 20.341 | 37.828 |
| Net Income Ratio
| -1.354 | -0.642 | -0.437 | -0.832 | -0.581 | -0.728 | -0.797 | 30.588 | 0.893 | 0.026 | 0.031 | 0.052 | 0.09 |
| EPS
| -0.096 | -0.072 | -0.044 | -0.064 | -0.081 | -0.1 | -0.1 | -0.71 | 0.28 | 0.012 | 0.015 | 0.024 | 0.047 |
| EPS Diluted
| -0.096 | -0.072 | -0.044 | -0.064 | -0.081 | -0.1 | -0.1 | -0.71 | 0.28 | 0.012 | 0.015 | 0.024 | 0.047 |
| EBITDA
| -228.568 | -144.393 | -83.127 | -87.224 | -197.688 | -181.66 | -233.909 | -1,095.12 | 259.49 | 18.002 | 20.54 | 29.137 | 49.425 |
| EBITDA Ratio
| -1.151 | 0.021 | -0.044 | -0.216 | -0.266 | -0.34 | -0.558 | 17.059 | -0.452 | 0.043 | 0.047 | 0.075 | 0.118 |